William Blair Issues Positive Estimate for DNLI Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Research analysts at William Blair lifted their Q3 2025 earnings estimates for shares of Denali Therapeutics in a research note issued to investors on Tuesday, August 12th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($0.77) for the quarter, up from their prior forecast of ($0.84). William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. William Blair also issued estimates for Denali Therapeutics’ Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($3.49) EPS, FY2027 earnings at ($2.78) EPS and FY2028 earnings at ($0.41) EPS.

Several other research firms have also commented on DNLI. Robert W. Baird reduced their price target on shares of Denali Therapeutics from $30.00 to $29.00 and set an “outperform” rating for the company in a report on Thursday, May 8th. Wedbush reduced their price target on shares of Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, May 7th. Bank of America reduced their price target on shares of Denali Therapeutics from $28.00 to $27.00 and set a “buy” rating for the company in a report on Monday, May 19th. TD Cowen upgraded shares of Denali Therapeutics to a “strong-buy” rating in a report on Monday, July 28th. Finally, HC Wainwright reduced their price target on shares of Denali Therapeutics from $80.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $33.85.

Denali Therapeutics Trading Down 2.4%

Shares of DNLI opened at $14.46 on Thursday. Denali Therapeutics has a 1-year low of $10.57 and a 1-year high of $33.33. The company has a 50-day moving average of $14.30 and a 200 day moving average of $15.42. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of -5.16 and a beta of 1.36. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.27 and a quick ratio of 9.56.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.02. During the same quarter in the prior year, the business posted ($0.59) EPS.

Insider Buying and Selling

In related news, insider Alexander O. Schuth sold 2,937 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the transaction, the insider owned 242,346 shares in the company, valued at $3,291,058.68. The trade was a 1.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Carole Ho sold 2,937 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the sale, the insider directly owned 217,391 shares in the company, valued at approximately $2,952,169.78. This represents a 1.33% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 501,962 shares of company stock worth $7,520,799 in the last 90 days. 12.50% of the stock is owned by corporate insiders.

Institutional Trading of Denali Therapeutics

Several large investors have recently bought and sold shares of the stock. Wellington Management Group LLP grew its position in Denali Therapeutics by 15.9% during the 1st quarter. Wellington Management Group LLP now owns 11,409,598 shares of the company’s stock worth $155,113,000 after purchasing an additional 1,561,647 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Denali Therapeutics by 88.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company’s stock worth $91,996,000 after purchasing an additional 3,184,042 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Denali Therapeutics by 42.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,367,234 shares of the company’s stock worth $59,373,000 after purchasing an additional 1,308,619 shares during the last quarter. Norges Bank purchased a new stake in Denali Therapeutics during the 2nd quarter worth approximately $55,224,000. Finally, Geode Capital Management LLC grew its position in Denali Therapeutics by 4.4% during the 2nd quarter. Geode Capital Management LLC now owns 3,172,305 shares of the company’s stock worth $44,386,000 after purchasing an additional 135,129 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.